Pnd159 - Dramatic Improvement in Treatment Acceptance Observed in Patients With Multiple Sclerosis Switching Treatment: A Real-World Study

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2907
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

PND48 Real World Treatment Profile of Patients With Tuberous Sclerosis Complex

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2012English

Masitinib Treatment in Patients With Progressive Multiple Sclerosis: A Randomized Pilot Study

BMC Neurology
MedicineNeurology
2012English

Correction To: Switching From Natalizumab to Fingolimod Treatment in Multiple Sclerosis: Real Life Data From the Austrian MS Treatment Registry

Journal of Neurology
Neurology
2019English

Real-World Treatment of Patients With Multiple Sclerosis Per MS Subtype and Associated Healthcare Resource Use: An Analysis Based on 13,333 Patients in Germany

Neurology and Therapy
Neurology
2019English

Treatment Satisfaction in Multiple Sclerosis

International Journal of MS Care
NeurologySpecialized NursingAdvanced
2014English

Natalizumab Treatment in Multiple Sclerosis

Clinical Neurology
Neurology
2015English

Real-World Study of Efficacy, Risk Management and Reasons for Discontinuation of Natalizumab for Treatment of Multiple Sclerosis in Russia

PLoS ONE
Multidisciplinary
2019English

Testosterone Treatment in Multiple Sclerosis

Archives of Neurology
2007English

Fingolimod Treatment in Relapsing-Remitting Multiple Sclerosis Patients: A Prospective Observational Multicenter Postmarketing Study

Multiple Sclerosis International
Neurology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy